Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/01/2022* -- Results Q4 2021 -- -0.15 --
03/01/2022* 08:30 EST Earnings Call Q4 2021 -- -- --
11/09/2021 -- Results Q3 2021 -0.19 -0.18 -4.91%
11/09/2021 08:30 EST Earnings Call Q3 2021 -- -- --
08/05/2021 -- Results Q2 2021 -0.19 -0.20 6.86%
08/05/2021 08:30 EST Earnings Call Q2 2021 -- -- --
05/10/2021 -- Results Q1 2021 -0.25 -0.26 3.85%
05/10/2021 08:30 EST Earnings Call Q1 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 03/01/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/09/2021
Beat/Miss Upgrade
Return Since -19.35%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
URL https://www.amicusrx.com
Investor Relations URL https://ir.amicusrx.com
HQ State/Province Pennsylvania
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 01, 2022
Last Earnings Release Nov. 09, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
16.59%
-48.76%
189.5%
-33.43%
1.67%
137.1%
-49.98%
-20.95%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-6.93%
--
--
--
--
--
75.57%
-80.59%
35.64%
--
-71.79%
2.42%
-55.42%
-23.67%
610.1%
-66.00%
-5.64%
--
--
--
--
-83.01%
30.17%
220.3%
-25.00%
--
--
--
--
-16.34%
-43.76%
101.3%
-37.13%
As of January 28, 2022.

Profile

Edit
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
URL https://www.amicusrx.com
Investor Relations URL https://ir.amicusrx.com
HQ State/Province Pennsylvania
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 01, 2022
Last Earnings Release Nov. 09, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
NIFE 103391.0 USD 2.85%
F000015T09 214.00 USD 2.14%
F00001553S 212.00 USD 2.12%
SBIO 2.741M USD 2.02%
IHE 2.783M USD 0.73%
PHPSX 44804.00 USD 0.67%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits FOLD Tweets